Ratings Geratherm Medical AG

Equities

GME

DE0005495626

Market Closed - Xetra Other stock markets 11:36:04 2024-07-04 am EDT			5-day change	1st Jan Change
4.02 ^EUR	0.00%		-0.99%	-25.56%

Jun. 20	Geratherm Medical AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Geratherm Medical AG Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company does not generate enough profits, which is an alarming weak point.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
GERATHERM MEDICAL AG	-25.56%	23.35M	-
ABBOTT LABORATORIES	-7.03%	178B	C+
MEDTRONIC PLC	-6.32%	98.95B	C
BECTON, DICKINSON AND COMPANY	-6.15%	66.14B	A
DEXCOM, INC.	-10.62%	44.11B	B-
CENCORA, INC.	+8.34%	43.82B	B-
HOYA CORPORATION	+11.26%	42.07B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+11.64%	28.92B	B
TERUMO CORPORATION	+18.69%	24.69B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-8.87%	23.38B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes